Core Viewpoint - Baixinan-B (02185) has seen a nearly 10% increase in stock price, currently trading at 7.85 HKD, with a transaction volume of 11.7587 million HKD, following a strategic partnership announcement with Bluestar Medical (002382) for the Iberis RDN system [1] Company Summary - Baixinan has established a "going abroad" cooperation with Bluestar Medical, leveraging its platform capabilities and industry reputation [1] - The Iberis RDN system has achieved commercialization in countries such as Germany, Spain, and Italy, with Germany and France including it in their healthcare insurance [1] - The Iberis RDN system is the only one globally approved for both transradial (TRA) and transfemoral access routes, providing a significant first-mover advantage [1] Industry Summary - Percutaneous renal denervation (RDN) is a new therapeutic device for uncontrolled and resistant hypertension [1] - According to Frost & Sullivan, the annual market size for RDN in China is expected to exceed 10 billion RMB by 2032 [1] - The inclusion of the Iberis RDN system in the healthcare insurance of Germany and France is expected to accelerate Baixinan's commercialization efforts [1]

Core Viewpoint - Baixinan-B (02185) experienced a significant stock price increase, rising nearly 15% at the close, with a current price of 6.14 HKD and a trading volume of 16.9358 million HKD, indicating strong market interest and potential growth opportunities in the medical device sector [1] Company Developments - Bluefan Medical (002382) announced a strategic partnership with Baixinan for the Iberis multi-polar renal denervation (RDN) system, leveraging its platform capabilities and industry reputation to expand into international markets [1] - The Iberis RDN system has achieved commercialization in Germany, Spain, and Italy, with Germany and France including it in their healthcare insurance coverage, enhancing its market accessibility [1] - The system has recently received approval from the Singapore Health Sciences Authority for clinical use, marking a significant milestone in its international rollout [1] Market Potential - According to Zhi Shi Consulting, the annual market size for RDN in China is expected to exceed 10 billion RMB by 2032, highlighting the growth potential in this therapeutic area [1] - Huafu Securities noted that the Baixinan Iberis RDN system is the only one globally approved for both transradial (TRA) and transfemoral access routes, providing a significant first-mover advantage in the market [1] - The collaboration with Yuanda Health and various international partners is expected to accelerate Baixinan's commercialization efforts, positioning the company favorably in the competitive landscape [1]